Pupiloscope, a Neuro-Critical Care Device, Enabling Quantitative, Real-Time, Pupillary Monitoring and Assessment of Patients with Neurotrauma and Head Injuries.

Descripción del proyecto

Un nuevo dispositivo para la valoración pupilar objetiva

Los exámenes pupilares calculan el tamaño y forma de la pupila en reposo, así como su respuesta a la aplicación de luz a los ojos. Se basan en el control neurológico de la pupila y sirven para diagnosticar diversas afecciones, como lesiones tras traumatismos craneoencefálicos. El proyecto PUPILOSCOPE, financiado con fondos europeos, ha desarrollado una revolucionaria tecnología que permite el control cuantitativo al instante de las respuestas pupilares. El nuevo dispositivo se basa en la idea de evitar la naturaleza humana y propensa a errores de los exámenes pupilares convencionales. Algo importante es que no requiere una formación especializada y constituye una potente herramienta en la medicina de urgencias, especialmente para pacientes con traumatismos craneoencefálicos.

Objetivo

An estimated 42 million people Worldwide suffer a Head Injury (2.5 million in the EU) that can lead to Mild or Traumatic Brain Injury (TBI). It is a major cause of death and disability, especially in young people, impacting victims and relatives, with significant costs to society, estimated at €33 Billion per annum in Europe alone.

Pre-Hospital and Emergency Care Neuro-Monitoring, including pupillary assessment, is critical in the processes of triage, management and medicating patients to prevent secondary injury to the brain. However, the current method of shining a light into a patient's eyes, in order to estimate pupillary response, is subjective and prone to human error.

The solution is Pupiloscope®, enabling Accurate, Real-time, Quantitative Pupillary Monitoring and Assessment for patients with potentially life threatening head injuries. Pupiloscope is a breakthrough technology that will positively impact clinical pathways as well as patient outcomes. It is quick, simple, and easy to use by Doctors, Nurses and Paramedics of all skill levels. Through collaboration with industry experts, key opinion leaders, engineers and Emergency Care based clinicians, who identified the unmet clinical need, ViVO has successfully developed a functional prototype to TRL 6.

As a direct result of this project, Pupiloscope forecasts sales of €20 Million within 5 years of product launch, improving patient outcomes and reducing both the societal and costs of care in the EU and Globally by an estimated €2 Billion per annum.

This project will seek to develop Pupiloscope into a clinically proven, manufacturing ready and CE approved medical device; incorporating technology finalisation, regulatory approval, health economics, clinical testing and validation, therefore enabling product launch and sales to the EU and Global Emergency Care healthcare markets.

Ámbito científico

Palabras clave

Programa(s)

Tema(s)

EIC-SMEInst-2018-2020 - SME instrument

Convocatoria de propuestas

H2020-EIC-SMEInst-2018-2020

Consulte otros proyectos de esta convocatoria

Convocatoria de subcontratación

H2020-SMEInst-2018-2020-2

Régimen de financiación

SME-2 - SME instrument phase 2

Coordinador

VIVO SMART MEDICAL DEVICES LTD

Aportación neta de la UEn

€ 875 637,88

Dirección

6 EDISON VILLAGE NOTTINGHAM SCIENCE TECHNOLOGY PARK
NG7 2RF Nottingham
Reino Unido

Pyme

Sí

Región

East Midlands (England) Derbyshire and Nottinghamshire Nottingham

Tipo de actividad

Private for-profit entities (excluding Higher or Secondary Education Establishments)

Enlaces

Contactar con la organización

Participación en los programas de I+D de la UE

Red de colaboración de HORIZON

Coste total

€ 1 250 911,25